Assertio Historical Balance Sheet
ASRT Stock | USD 0.96 0.04 4.00% |
Trend analysis of Assertio Therapeutics balance sheet accounts such as Short Long Term Debt Total of 38.9 M, Other Current Liabilities of 83 M or Total Current Liabilities of 72.3 M provides information on Assertio Therapeutics' total assets, liabilities, and equity, which is the actual value of Assertio Therapeutics to its prevalent stockholders. By breaking down trends over time using Assertio Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Assertio Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Assertio Therapeutics is a good buy for the upcoming year.
Assertio Therapeutics Inventory |
|
Assertio |
About Assertio Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Assertio Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Assertio Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Assertio Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Assertio currently owns. An asset can also be divided into two categories, current and non-current.
Assertio Therapeutics Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Assertio Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Assertio Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Assertio Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Assertio Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Property Plant And Equipment Net
The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.Most accounts from Assertio Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Assertio Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Assertio Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Assertio Stock please use our How to Invest in Assertio Therapeutics guide.At this time, Assertio Therapeutics' Total Liabilities is comparatively stable compared to the past year. Cash is likely to gain to about 80.2 M in 2024, whereas Total Stockholder Equity is likely to drop slightly above 93.7 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 73.5M | 66.9M | 40.9M | 38.9M | Total Assets | 326.5M | 413.9M | 286.4M | 336.5M |
Assertio Therapeutics balance sheet Correlations
Click cells to compare fundamentals
Assertio Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Assertio Therapeutics balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 527.2M | 303.3M | 326.5M | 413.9M | 286.4M | 336.5M | |
Short Long Term Debt Total | 351.3M | 84.1M | 73.5M | 66.9M | 40.9M | 38.9M | |
Other Current Liab | 2.1M | 103.3M | 114.2M | 88.5M | 79.1M | 83.0M | |
Total Current Liabilities | 184.6M | 132.7M | 135.0M | 95.3M | 93.4M | 72.3M | |
Total Stockholder Equity | 58.0M | 55.5M | 102.4M | 225.7M | 138.0M | 93.7M | |
Property Plant And Equipment Net | 3.5M | 2.4M | 1.5M | 744K | 2.0M | 1.9M | |
Net Debt | 309.2M | 63.3M | 36.7M | 1.9M | (32.5M) | (30.9M) | |
Retained Earnings | (399.8M) | (427.9M) | (429.2M) | (319.6M) | (651.5M) | (619.0M) | |
Accounts Payable | 16.2M | 14.8M | 6.7M | 6.0M | 13.4M | 15.6M | |
Non Current Assets Total | 423.2M | 209.0M | 223.0M | 281.7M | 115.4M | 203.4M | |
Non Currrent Assets Other | 6.1M | 4.9M | 5.5M | 2.4M | 2.0M | 2.1M | |
Net Receivables | 42.7M | 44.4M | 44.4M | 45.4M | 47.7M | 26.3M | |
Common Stock Shares Outstanding | 17.7M | 26.2M | 43.2M | 54.7M | 71.0M | 74.6M | |
Liabilities And Stockholders Equity | 527.2M | 303.3M | 326.5M | 413.9M | 286.4M | 336.5M | |
Other Current Assets | 15.7M | 34.8M | 29.7M | 16.5M | 24.2M | 25.5M | |
Total Liab | 469.2M | 247.8M | 224.1M | 188.2M | 148.4M | 242.8M | |
Total Current Assets | 104.0M | 94.3M | 103.5M | 132.3M | 171.1M | 133.1M | |
Short Term Debt | 80M | 14.6M | 14.2M | 871K | 928K | 881.6K | |
Cash | 42.1M | 20.8M | 36.8M | 64.9M | 73.4M | 80.2M | |
Cash And Short Term Investments | 42.1M | 20.8M | 36.8M | 64.9M | 73.4M | 95.5M | |
Non Current Liabilities Total | 284.7M | 115.1M | 89.1M | 92.9M | 55.0M | 52.2M | |
Other Stockholder Equity | 457.8M | 483.4M | 531.6M | 545.3M | 789.5M | 829.0M | |
Common Stock | 8K | 13K | 4K | 5K | 9K | 8.6K | |
Other Assets | 3.3M | 206.6M | 5.5M | 82.5M | 1.0 | 0.95 | |
Long Term Debt | 271.3M | 72.2M | 61.3M | 66.4M | 38.2M | 36.3M | |
Property Plant Equipment | 3.5M | 4.8M | 1.5M | 881K | 1.0M | 962.5K | |
Current Deferred Revenue | (2.4M) | 86.3M | 96.5M | 67.4M | 77.5M | 42.0M | |
Common Stock Total Equity | 313.9M | 6K | 8K | 13K | 11.7K | 11.1K | |
Property Plant And Equipment Gross | 3.5M | 2.4M | 1.5M | 744K | 6.7M | 5.7M | |
Other Liab | 8.6M | 40.1M | 27.8M | 26.5M | 23.8M | 29.7M | |
Inventory | 3.4M | 11.7M | 7.5M | 13.7M | 37.7M | 39.6M | |
Net Tangible Assets | (342.6M) | (144.6M) | (113.6M) | 27.7M | 25.0M | 26.2M | |
Non Current Liabilities Other | 13.4M | 42.9M | 27.8M | 26.5M | 9.2M | 8.8M | |
Intangible Assets | 400.5M | 200.1M | 216.1M | 198.0M | 111.3M | 105.8M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Assertio Stock Analysis
When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.